Enzon's PEG-L-asparaginase
Executive Summary
Clinical trial comparing the firm's investigational agent to L-asparaginase marketed by Merck (Elspar) and an investigational version produced by the National Cancer Institute (Erwinase) in acute lymphocytic leukemia began Nov. 17 at six centers in U.S. Trial, partially supported by NCI, includes 150 children with newly diagnosed acute lymphocytic leukemia. Study centers include the Dana-Farber Cancer Institute in Boston, University of Puerto Rico, Maine Medical Center, University of Rochester, Ochsner Clinic in New Orleans, and the University of Massachusetts.